本公司及董事会全体成员保证公告内容真实、准确和完整，并对公告中的 虚假记载、误导性陈述或者重大遗漏承担责任。 特别提示： | 证券代码：301069 | 证券简称：凯盛新材 公告编号：2025-023 | | --- | --- | | 债券代码：123233 | 债券简称：凯盛转债 | 山东凯盛新材料股份有限公司 关于可转换公司债券转股价格调整的提示性公告 1、债券代码：123233 2、债券简称：凯盛转债 3、本次调整前"凯盛转债"转股价格：20.06 元/股 4、本次调整后"凯盛转债"转股价格：20.01 元/股 5、本次转股价格调整生效日期：2025 年 4 月 30 日（股利分配除权除息日） 一、可转换公司债券基本情况 根据中国证券监督管理委员会《关于同意山东凯盛新材料股份有限公司向不 特定对象发行可转换公司债券注册的批复》（证监许可〔2023〕1893 号），山 东凯盛新材料股份有限公司（以下简称"公司"）获准向不特定对象发行可转换 公司债券 650.00 万张，每张面值为人民币 100.00 元，募集资金总额为 650,000,000.00 元。经深圳证券交易所同意，公司本次向不特定对象发行的可 ...

Overall Overview - Company achieved total operating revenue of 269 million yuan in Q1 2025, representing a year-on-year increase of 12.28% [1] - Net profit attributable to shareholders reached 30.67 million yuan, up 19.35% year-on-year [1] - Deducting non-recurring gains and losses, net profit was 27.69 million yuan, reflecting a year-on-year growth of 27.72% [1] Key Financial Indicators Analysis Profitability - Gross margin stood at 29.7%, an increase of 11.31% compared to the same period last year, indicating improved cost control [2] - Net margin was 11.38%, up 6.65% year-on-year, showing enhanced profitability [2] - Earnings per share were 0.07 yuan, a year-on-year increase of 19.31%, reflecting value appreciation for shareholders [2] Operational Efficiency - The ratio of three expenses (selling, administrative, and financial expenses) to revenue was 8.62%, a decrease of 15.52% from the previous year, indicating effective cost management [2] Asset and Liability Status - Cash and cash equivalents amounted to 465 million yuan, a year-on-year increase of 3.48%, indicating a solid cash reserve [2] - Accounts receivable reached 155 million yuan, a significant year-on-year increase of 47.59%, raising concerns about collection risks [2] - Interest-bearing debt totaled 521 million yuan, up 6.32% year-on-year, suggesting a need for attention to debt levels and interest burdens [2] - The ratio of interest-bearing debt to total assets was 21.61%, with interest-bearing debt amounting to 29.31% of the average operating cash flow over the past three years, indicating some debt risk [2] - Financial expenses accounted for 134.59% of the average operating cash flow over the past three years, further increasing the financial burden on the company [2] - The ratio of accounts receivable to profit reached 276.8%, necessitating caution regarding potential bad debt losses [2]

Financial Performance - The company reported a total revenue of 269 million yuan for Q1 2025, representing a year-on-year increase of 12.28% [1] - The net profit attributable to shareholders reached 30.67 million yuan, up 19.35% year-on-year [1] - The gross margin improved to 29.7%, an increase of 11.31% compared to the previous year [1] - The net profit margin also increased to 11.38%, reflecting a 6.65% year-on-year growth [1] - The company's operating cash flow per share decreased significantly by 79.18% to 0.01 yuan [1] Accounts Receivable and Debt - Accounts receivable rose to 155 million yuan, with a year-on-year growth of 47.59% [1] - Interest-bearing liabilities increased to 521 million yuan, marking a 6.32% rise [1] - The company's debt ratio for interest-bearing assets reached 21.61% [3] Research and Development - The company increased its R&D investment to approximately 53.8 million yuan in 2024, up from 51.5 million yuan in 2023 [5] - Several R&D projects have made progress, including studies on high-selectivity reactions and production processes [5] Market Expectations - Analysts expect the company's performance in 2025 to reach 80 million yuan, with an average earnings per share of 0.19 yuan [3]

| 证券代码：301069 | 证券简称：凯盛新材 公告编号：2025-020 | | --- | --- | | 债券代码：123233 | 债券简称：凯盛转债 | 山东凯盛新材料股份有限公司（以下简称"公司"）第三届监事会第二十七 次会议通知于 2025 年 4 月 15 日以电子邮件的形式发出，2025 年 4 月 18 日通过 通讯表决的方式召开，公司 3 名监事都参加了本次会议，会议的通知及召开符合 《公司法》及《公司章程》的规定，合法有效。本次会议由监事会主席张善民先 生主持，经与会各位监事认真讨论研究，审议并通过了以下议案： （一）会议以 3 票赞成、0 票反对、0 票弃权的表决结果审议通过了《山 东凯盛新材料股份有限公司 2025 年第一季度报告》。 详见公司于同日在巨潮资讯网（www.cninfo.com.cn）披露的《山东凯盛新 材料股份有限公司 2025 年第一季度报告》。 （二）会议以 3 票赞成、0 票反对、0 票弃权的表决结果审议通过了《关 于对山东凯盛新材料股份有限公司 2025 年第一季度报告的审议意见的议案》。 经过对公司《2025 年第一季度报告》进行全面的审核后，监事会认 ...

山东凯盛新材料股份有限公司 第三届董事会第三十一次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 一、会议召开及议案审议情况 | 证券代码：301069 | 证券简称：凯盛新材 公告编号：2025-019 | | --- | --- | | 债券代码：123233 | 债券简称：凯盛转债 | 详见公司于同日在巨潮资讯网（www.cninfo.com.cn）披露的《关于 2022 年 限制性股票激励计划首次授予部分第二及第三个归属期、预留授予部分第一及第 二个归属期归属条件未成就暨作废已授予但尚未归属的限制性股票的公告》（公 告编号：2025-021）。 详见公司于同日在巨潮资讯网（www.cninfo.com.cn）披露的《山东凯盛新材 料股份有限公司 2025 年第一季度报告》。 （二）以 7 票赞成、0 票反对、0 票弃权的表决结果审议通过了《关于 2022 年限制性股票激励计划首次授予部分第二及第三个归属期、预留授予部分第一 及第二个归属期归属条件未成就暨作废已授予但尚未归属的限制性股票的议 案》。 因王永先生为激励对象，故关联 ...

| 证券代码：301069 | 证券简称：凯盛新材 公告编号：2025-021 | | --- | --- | | 债券代码：123233 | 债券简称：凯盛转债 | 关于2022年限制性股票激励计划首次授予部分第二及第三个归属 期、预留授予部分第一及第二个归属期归属条件未成就暨作废 已授予但尚未归属的限制性股票的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，并对公告中的虚 假记载、误导性陈述或者重大遗漏承担责任。 特别提示： 1、根据《2022 年限制性股票激励计划（草案）》的规定，公司 2022 年限制 性股票激励计划首次授予部分第二个及第三个归属期、预留授予部分第一及第 二个归属期均未满足公司层面业绩考核要求，归属条件未成就，激励对象已获授 予但尚未归属的合计 158.32 万股限制性股票全部取消归属，并作废失效。 2、涉及 2022 年限制性股票激励计划的相关事宜全部办理终结。 山东凯盛新材料股份有限公司（以下简称"公司"）于 2025 年 4 月 18 日召 开了第三届董事会第三十一次会议和第三届监事会第二十七次会议，审议通过了 《关于 2022 年限制性股票激励计划首次授予部分第二及第 ...

关于山东凯盛新材料股份有限公司 2022 年限制性股票 激励计划首次授予部分第二及第三个归属期、预留授予部分 第一及第二个归属期归属条件未成就暨作废 已授予但尚未归属的限制性股票事项的法律意见书 北京市时代九和律师事务所 关于山东凯盛新材料股份有限公司 2022 年限制性股票激励计划首次授予部分第二及第三个归属 期、预留授予部分第一及第二个归属期归属条件未成就暨作废已 授予但尚未归属的限制性股票事项的法律意见书 致：山东凯盛新材料股份有限公司： 北京市时代九和律师事务所（以下简称"本所"）受山东凯盛新材料股份有 限公司（以下简称"公司"或"凯盛新材"）委托，作为凯盛新材 2022 年限制性 股票激励计划（以下简称"本次股权激励计划"、"本激励计划"）的专项法律 顾问，根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公 司股权激励管理办法》（以下简称"《股权激励管理办法》"）、《深圳证券交 易所创业板股票上市规则》、《深圳证券交易所创业板上市公司自律监管指南第 1 号——业务办理》等法律法规、规范性文件以及《山东凯盛新材料股份有限公 司章程》、《山东凯盛新材料股份有限公司 2022 年限制性股票激 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 269,395,580.18, representing a 12.28% increase compared to CNY 239,937,179.44 in the same period last year[5]. - Net profit attributable to shareholders was CNY 30,670,161.17, up 19.35% from CNY 25,698,384.59 year-on-year[5]. - The net profit after deducting non-recurring gains and losses increased by 27.72%, reaching CNY 27,689,248.68 compared to CNY 21,679,169.31 in the previous year[5]. - Total operating revenue for the current period reached ¥269,395,580.18, an increase of 12.4% compared to ¥239,937,179.44 in the previous period[19]. - Operating profit for the current period was ¥37,670,368.76, up from ¥31,233,126.62, reflecting a growth of 20.8%[20]. - Net profit attributable to the parent company was ¥30,670,161.17, compared to ¥25,698,384.59 in the previous period, marking an increase of 19.3%[20]. - The company reported a basic and diluted earnings per share of ¥0.0729, compared to ¥0.0611 in the previous period, an increase of 19.7%[20]. Cash Flow and Investments - The company's cash flow from operating activities decreased significantly by 79.18%, amounting to CNY 2,858,216.65, down from CNY 13,726,887.23 in Q1 2024[5]. - Cash flow from operating activities was ¥131,558,597.52, down from ¥181,110,877.58, indicating a decrease of 27.4%[22]. - The net increase in cash and cash equivalents was $34,154,324.42, contrasting with a decrease of $404,841,682.46 last year[24]. - The ending balance of cash and cash equivalents stood at $456,014,960.39, up from $415,726,948.25 in the previous period[24]. - The company received $1,195,552,077.15 in cash from investment recoveries, a notable increase from $800,684,537.59[23]. - Cash received from investment income was $2,231,443.06, compared to $1,887,467.14 in the previous year[23]. - Cash paid for the purchase of fixed assets and intangible assets was $2,303,558.00, slightly down from $2,558,233.48[23]. Assets and Liabilities - Total assets at the end of Q1 2025 were CNY 2,410,569,005.89, a 0.91% increase from CNY 2,388,723,256.19 at the end of the previous year[5]. - Total current assets amounted to ¥1,407,470,348.44, up from ¥1,348,622,039.44, representing a growth of approximately 4.3%[16]. - The company's fixed assets decreased to ¥660,189,685.87 from ¥682,377,368.42, a decline of about 3.2%[16]. - Total liabilities decreased to ¥743,702,051.64 from ¥752,641,539.99, indicating a reduction of 1.8%[18]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 22,203[11]. - The largest shareholder, Huabang Life Health, holds 44.51% of shares, totaling 187,216,000 shares[11]. - The number of shares held by the top ten unrestricted shareholders includes 187,216,000 shares from Huabang Life Health[11]. - Wang Jiarong and Wang Yong, both significant shareholders, have locked shares totaling 12,000,000 and 11,760,000 respectively[14]. - The company has not reported any changes in the participation of major shareholders in margin trading[12]. Research and Development - Research and development expenses surged by 86.34% to CNY 19,541,083.56, reflecting increased investment in R&D[9]. - Research and development expenses increased significantly to ¥19,541,083.56, up from ¥10,486,648.77, representing an increase of 86.7%[19]. Equity and Returns - The weighted average return on equity improved to 1.86%, up from 1.53% in the same period last year[5]. - The total equity attributable to shareholders increased by 1.88% to CNY 1,666,866,954.25 compared to CNY 1,636,081,716.20 at the end of the previous year[5]. - The total equity attributable to shareholders increased to ¥1,666,866,954.25 from ¥1,636,081,716.20, reflecting a growth of 1.9%[18]. Other Information - There are no new strategies or significant developments reported in the current quarter[15]. - The company did not conduct an audit for the first quarter report[25].

凯盛新材（301069）公告，2025年第一季度营业收入2.69亿元，同比增长12.28%。净利润3067.02万 元，同比增长19.35%。 ...

| 证券代码：301069 | 证券简称：凯盛新材 | 公告编号：2025-018 | | --- | --- | --- | | 转债代码：123233 | 债券简称：凯盛转债 | | 2025 年 3 月 20 日，华邦健康获得深圳证券交易所出具的《关于华邦生命健 康股份有限公司非公开发行科技创新可交换公司债券符合深交所挂牌条件的无 异议函》（深证函〔2025〕249 号），拟非公开发行可交换公司债券期限为 3 年， 拟募集资金规模不超过人民币 6 亿元。 2025 年 4 月 10 日，公司接到华邦健康通知："华邦生命健康股份有限公司 2025年非公开发行可交换公司债券"（债券简称为"25华邦EB"，以下简称"本 期债券"）将采用股票担保形式，即华邦健康将以其持有的本公司部分股票作为 担保并办理担保及信托登记，以保障本期债券持有人交换本公司股票和本期债 券本息按照约定如期足额兑付，华邦健康拟将其持有的本公司 60,000,000 股股 票自其证券账户划入担保及信托专户，详见公司于 2025 年 4 月 10 日在巨潮资讯 网（http://www.cninfo.com.cn）等指定信息披露媒体上发布的《 ...